excerpt DYNAMIC's pre-specified de-escalation finding: in stage II colon cancer randomized 2:1 to ctDNA-guided vs standard clinicopathological management (N=455; ctDNA assayed at weeks 4/7 post-resection), adjuvant chemotherapy use was substantially reduced in the ctDNA-guided arm (15% vs 28%) while 2-year recurrence-free survival met the pre-specified noninferiority criterion (lower 95% CI bound −4.1 percentage points vs noninferiority margin of −8.5 pp). This is the strongest randomized evidence directly addressing the sub-topic's central question — whether ctDNA-negativity in the MRD window justifies de-escalation of adjuvant chemotherapy after resection of stage II colon cancer. Scope match is exact (stage II colon cancer, post-resection MRD window via weeks 4/7 ctDNA, adjuvant decision as outcome of guidance), so unlike the GALAXY/BESPOKE observational anchors, no population caveat is needed. Note: the chemotherapy-use difference is the secondary endpoint that operationalizes "de-escalation"; the noninferior RFS is the primary endpoint that licenses it. Both pieces are needed to interpret the trial's bearing.
nod_11726864-69d3-4156-bd40-c5d641ed2083
Quoted span
A lower percentage of patients in the ctDNA-guided group than in the standard-management group received adjuvant chemotherapy (15% vs. 28%; relative risk, 1.82; 95% confidence interval [CI], 1.25 to 2.65).
Provenance
- Proposed by idn_fc20fc7c-7b35-4993-8d7f-3e1d87a1eba2
- Created 2026-06-04T08:38:13.976Z
- Status: active